



Summary of Studies Supporting USDA Product Licensure

Establishment Name	Intervet Inc.
USDA Vet Biologics Establishment Number	165A
Product Code	2775.02
True Name	Mycoplasma Hyopneumoniae Bacterin
Tradename(s) / Distributor or Subsidiary (if different from manufacturer)	Myco Silencer ONCE - Intervet Argentina S.A. Myco Silencer ONCE - Merck Animal Health Myco Silencer ONCE - No distributor specified Porcilis Myco Silencer ONCE - Intervet Mexico S.A. de C.V. Porcilis Myco Silencer ONCE - Intervet Mexico S.A. de C.V. - Merck Sharpe and Dohme (MSD) Porcilis Myco Silencer ONCE - Intervet Thailand Ltd
Date of Compilation Summary	October 27, 2021

Disclaimer: Do not use the following studies to compare one product to another. Slight differences in study design and execution can render the comparisons meaningless.

Study Type	Efficacy																												
Pertaining to	<i>Mycoplasma hyopneumoniae</i>																												
Study Purpose	Demonstrate 23 weeks DOI against pneumonia caused by <i>Mycoplasma hyopneumoniae</i>																												
Product Administration	One dose IM																												
Study Animals	Total of 48 three-week-old pigs, grouped into 24 vaccinated and 24 control group																												
Challenge Description	Pigs were challenged 23 weeks post vaccination, intranasally with virulent <i>Mycoplasma hyopneumoniae</i> .																												
Interval observed after challenge	At 3 weeks post challenge, lung lesions were evaluated.																												
Results	<table border="1"> <thead> <tr> <th colspan="7">Five number summary of lung lesion scores</th> </tr> <tr> <th>Groups</th> <th>N</th> <th>Minimum</th> <th>25th percentile</th> <th>Median</th> <th>75th percentile</th> <th>Maximum</th> </tr> </thead> <tbody> <tr> <td>Vaccinated (Group 1)</td> <td>24</td> <td>0</td> <td>0</td> <td>0.2</td> <td>7.7</td> <td>32.7</td> </tr> <tr> <td>Control (Group 2)</td> <td>24</td> <td>0</td> <td>1.9</td> <td>8.3</td> <td>25.3</td> <td>48.1</td> </tr> </tbody> </table> <p>Raw data is presented in tables below.</p>	Five number summary of lung lesion scores							Groups	N	Minimum	25 th percentile	Median	75 th percentile	Maximum	Vaccinated (Group 1)	24	0	0	0.2	7.7	32.7	Control (Group 2)	24	0	1.9	8.3	25.3	48.1
Five number summary of lung lesion scores																													
Groups	N	Minimum	25 th percentile	Median	75 th percentile	Maximum																							
Vaccinated (Group 1)	24	0	0	0.2	7.7	32.7																							
Control (Group 2)	24	0	1.9	8.3	25.3	48.1																							
USDA Approval Date	June 6, 2001																												

Lung Lesion Score (LLS):

Group 1 Vaccinated

Group	Pig	LLS
1	2169	0
1	2170	5
1	2171	0
1	2172	0
1	2173	3.8
1	2174	20.6
1	2175	9.4
1	2176	5.9
1	2177	2.4
1	2178	0
1	2179	19.8
1	2180	0
1	2181	0.4
1	2182	0
1	2183	13.5
1	2184	0
1	2185	32.7
1	2186	0
1	2187	0
1	2189	0
1	2190	2.1
1	2191	0
1	2192	0
1	2193	9.7

Group 2 Control

Group	Pig	LLS
2	2094	30.6
2	2095	14.4
2	2096	0
2	2097	32.6
2	2098	2.8
2	2099	20.1
2	2100	17.2
2	2101	48.1
2	2102	2.3
2	2103	0.4
2	2104	0
2	2105	11.5
2	2106	8
2	2107	24
2	2108	3.7
2	2109	7.6
2	2110	0
2	2111	26.9
2	2112	27
2	2114	7.6
2	2115	8.6
2	2116	1.4
2	2117	0.8
2	2118	26.5

Study Type	Efficacy
Pertaining to	<i>Mycoplasma hyopneumoniae</i>
Study Purpose	Efficacy against pneumonia caused by <i>Mycoplasma hyopneumoniae</i>
Product Administration	IM
Study Animals	3-week-old pigs
Challenge Description	
Interval observed after challenge	
Results	Study data were evaluated by USDA-APHIS prior to product licensure and met regulatory standards for acceptance at the time of submission. No data are published because this study was submitted to USDA-APHIS prior to January 1, 2007, and APHIS only requires publication of data submitted after that date.
USDA Approval Date	December 18, 2001

Study Type	Safety
Pertaining to	<i>Mycoplasma hyopneumoniae</i>
Study Purpose	To demonstrate field safety of product
Product Administration	Single dose, IM
Study Animals	A total of 1,317 pigs, 3-weeks-of-age were vaccinated and monitored from four herds in distance geographical areas. Pigs were observed for systemic events, localized injection site events, and palpable lesions.
Challenge Description	N/A
Interval observed after challenge	N/A
Results	Out of 1,317 pigs, vaccinated only one systemic type event was noted and no mortalities were reported attributable to vaccination. Localized injection site swellings and/or redness were observed. See the summary table below.
USDA Approval Date	November 14, 2001

Adverse Event Summary Table

Herd	PL Serial	± Animals	EVENTS:		PALPATION:	
			Systemic	Local	Animals	Nodules
1	7881501	195	0	11 ^b	--	
	7881502	186	1 ^a	10 ^b	--	
2	7881501	170	0	1 ^c	42	1 ^c
	7881502	179	0	1 ^b	42	1 ^f
3	7881501	125	0	0	35 ^e	1 ^f
	7881502	133	0	0	42 ^e	1 ^f
4	7881501	162	0	0	36	2 ^f
	7881502	167	0	1 ^d	36	0
Serials:	7881501	652	0	12	113	4
	7881502	665	1	12	120	2
Totals		1,317	1 (0.08)	24 (1.8%)	233	6 (2.6%)

a – allergic like paddling event, resolved untreated within 2 minutes

b – transient redness or swelling at 24 hours post-injection, most resolved by 48 hours

c – reddened spot noted at 14 days, along with BB-sized palpable nodule (same pig)

d – swelling noted at 7 days, resolved by 14 days

e – 7 head per pen estimate

f – 0.5 – 1.0 cm firm palpable nodules noted at 14 days

Study Type	Safety
Pertaining to	<i>Mycoplasma hyopneumoniae</i>
Study Purpose	To demonstrate field safety of product
Product Administration	2 doses: 1 mL dose at 3 weeks of age or older followed by a second 1 mL dose 21 days later
Study Animals	Pigs 3-4 weeks of age
Challenge Description	
Interval observed after challenge	
Results	Study data were evaluated by USDA-APHIS prior to product licensure and met regulatory standards for acceptance at the time of submission.
USDA Approval Date	2005